Premium
Successful treatment with daclizumab of refractory anaplastic lymphoma
Author(s) -
Costa Vítor,
Oliva Teresa,
Norton Lucília
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22177
Subject(s) - daclizumab , medicine , anaplastic large cell lymphoma , lymphoma , oncology , refractory (planetary science) , monoclonal antibody , chemotherapy , malignant lymphoma , immunology , antibody , physics , astrobiology
Abstract Anaplastic large cell lymphoma (ALCL) is a relatively rare and highly malignant form of non‐Hodgkin lymphoma (NHL) which accounts for 10–15% of these childhood lymphomas. Current treatment protocols for ALCL in children consist of a short course of high intensity polychemotherapy. Here we describe an 8‐year‐old female with relapsed ALCL who achieved good response with anti‐CD25 monoclonal antibody daclizumab. Daclizumab appears to offer a safe treatment option, but further research needs to be conducted in order to define its role in children with ALCL who do not respond to intensive chemotherapy. Pediatr Blood Cancer 2009;53:1130–1131. © 2009 Wiley‐Liss, Inc.